Clinical Trials in Florida

Showing 2601-2620 of 10,975 trials

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

NCT05913232

The trial will evaluate the safety and efficacy of 3 dose regimens of H-1337 \[0.6% twice daily (b.i.d.), 1.0% b.i.d. and 1.0% once in the morning (q.a.m.), and timolol maleate (0.5%, b.i.d.) in both eyes for 28 days.

Glaucoma Open-Angle PrimaryOcular Hypertension

D. Western Therapeutics Institute, Inc.201 participantsStarted Aug 2023

Glendale, California, United States • Colorado Springs, Colorado, United States • Lakeland, Florida, United States +6 more locations

RECRUITINGPhase 249 miles

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

NCT03463460

This phase II trial studies how well pembrolizumab and sunitinib malate work in treating participants with thymic cancer that has spread to other places in the body or cannot be removed by surgery and does not respond to treatment. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and sunitinib malate may work better in treating thymic cancer.

Thymic Carcinoma

Dwight Owen30 participantsStarted Jun 2018

Tampa, Florida, United States • Indianapolis, Indiana, United States • Columbus, Ohio, United States

Study of Safety and Efficacy of H-1337 in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Find Trials by Condition in Florida

A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease

Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1)

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

INNOVEN: Efficacy of Porcine Placental Extracellular Matrix Plus Standard of Care (SOC) Versus SOC Alone

Study of INV-102 Ophthalmic Solution in Adults With Acute Infectious Keratoconjunctivitis

A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Study of JK07 in Patients With Chronic Heart Failure

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials

ERG Components in Schizophrenia and Bipolar Disorder Type I

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging

The Diabetes Prevention Program Outcomes Study AD/ADRD Project

Hospital Implementation of a Stroke Protocol for Emergency Evaluation and Disposition

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours